Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

Published byΠολύμνια Μαυρίδης Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher."— Presentation transcript:

1 Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher than blood pool. (A) Entire tumor load showed pertinent tracer uptake; (B) dominant part of tumor load showed tracer uptake; (C) minor part of tumor load showed tracer uptake; (D) entire tumor load lacked tracer uptake. From: Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial Ann Oncol. 2015;27(4): doi: /annonc/mdv577 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please 1

Download ppt "Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher."

Similar presentations

How to manage suspected cancer

How to manage suspected cancer
From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Fig. 1 Graphical representation

Fig. 1 Graphical representation
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.

Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser
Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.
Figure 2. Illustration of minimum cross-sectional area (a) and measurements for oropharynx and soft palate in sagittal plane (b, c). From: Airway volume.

Figure 2. Illustration of minimum cross-sectional area (a) and measurements for oropharynx and soft palate in sagittal plane (b, c). From: Airway volume.

Similar presentations

Ads by Google